Free Newsletter
China spawns a new wave of generics
Meanwhile, China's generics industry is gearing up for an onslaught on the U.S. market. A drug maker this summer won the first FDA approval for a Chinese-made pill, in this case, an HIV remedy; others aren't far behind. And when you consider that India's drug exports were few and far between just 10 years ago--and how that country's drug industry has affected pharma since--it's clear that a Chinese push could send enormous ripples through the market.
The country already has a big presence in active-ingredient manufacturing. That's a base generics-makers can build upon fairly quickly. Take the company that won approval for its version of the HIV drug nevirapine, Zhejiang Huahai Pharmaceutical--it's hoping to export an Alzheimer's drug to Europe as early as next year. The question is, will the rest of the world's drug makers be ready for the challenge?
- read the report from the Wall Street Journal (sub. req.)
Related Articles:
China's pharma market steams ahead. Report
Analyst: Generics makers sitting pretty. Report
Patent 'cliff' looms for Big Pharma. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





